Logo image of GTS

Triple S Management Corporation (GTS) Stock Fundamental Analysis

NYSE:GTS - New York Stock Exchange, Inc. - Common Stock

35.99  +0.37 (+1.04%)

After market: 35.98 -0.01 (-0.03%)

Fundamental Rating

2

Overall GTS gets a fundamental rating of 2 out of 10. We evaluated GTS against 108 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of GTS have multiple concerns. GTS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GTS was profitable.
GTS Yearly Net Income VS EBIT VS OCF VS FCFGTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 100M 200M

1.2 Ratios

Industry RankSector Rank
ROA 2.54%
ROE 7.98%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GTS Yearly ROA, ROE, ROICGTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 5 -5

1.3 Margins

GTS does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 1.97%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GTS Yearly Profit, Operating, Gross MarginsGTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 2 -2 4

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for GTS has been reduced compared to 1 year ago.
GTS has a better debt/assets ratio than last year.
GTS Yearly Shares OutstandingGTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M
GTS Yearly Total Debt VS Total AssetsGTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 1B 2B 3B

2.2 Solvency

A Debt/Equity ratio of 0.05 indicates that GTS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
GTS Yearly LT Debt VS Equity VS FCFGTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 200M 400M 600M 800M

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A

More info and screens

5

3. Growth

3.1 Past

GTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.55%.
The Earnings Per Share has been growing by 18.39% on average over the past years. This is quite good.
GTS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.10%.
GTS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.95% yearly.
EPS 1Y (TTM)-49.55%
EPS 3Y22.18%
EPS 5Y18.39%
EPS Q2Q%-32.79%
Revenue 1Y (TTM)16.1%
Revenue growth 3Y8.28%
Revenue growth 5Y4.95%
Sales Q2Q%9.72%

3.2 Future

GTS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.09% yearly.
GTS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.03% yearly.
EPS Next Y74.89%
EPS Next 2Y6.2%
EPS Next 3Y4.09%
EPS Next 5YN/A
Revenue Next Year6.28%
Revenue Next 2Y8.25%
Revenue Next 3Y8.03%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GTS Yearly Revenue VS EstimatesGTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B
GTS Yearly EPS VS EstimatesGTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 21.17, the valuation of GTS can be described as rather expensive.
GTS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.62.
A Price/Forward Earnings ratio of 9.67 indicates a reasonable valuation of GTS.
GTS is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 21.17
Fwd PE 9.67
GTS Price Earnings VS Forward Price EarningsGTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.25
GTS Per share dataGTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

GTS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.28
PEG (5Y)1.15
EPS Next 2Y6.2%
EPS Next 3Y4.09%

More info and screens

0

5. Dividend

5.1 Amount

GTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Triple S Management Corporation

NYSE:GTS (1/31/2022, 8:10:42 PM)

After market: 35.98 -0.01 (-0.03%)

35.99

+0.37 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)03-04 2022-03-04/bmo
Inst Owners0.41%
Inst Owner Change0%
Ins Owners3.8%
Ins Owner Change0%
Market Cap856.20M
Analysts45
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 21.17
Fwd PE 9.67
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB N/A
EV/EBITDA 6.25
EPS(TTM)1.7
EY4.72%
EPS(NY)3.72
Fwd EY10.34%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS172.98
BVpS42.78
TBVpSN/A
PEG (NY)0.28
PEG (5Y)1.15
Profitability
Industry RankSector Rank
ROA 2.54%
ROE 7.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.97%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.55%
EPS 3Y22.18%
EPS 5Y18.39%
EPS Q2Q%-32.79%
EPS Next Y74.89%
EPS Next 2Y6.2%
EPS Next 3Y4.09%
EPS Next 5YN/A
Revenue 1Y (TTM)16.1%
Revenue growth 3Y8.28%
Revenue growth 5Y4.95%
Sales Q2Q%9.72%
Revenue Next Year6.28%
Revenue Next 2Y8.25%
Revenue Next 3Y8.03%
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A